Go back to trials list
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
Description
This clinical trial assesses how the immune system responds to leukemia tumors after low dose radiation delivered as part of standard of care. The information learned in this study may help them know if adding immunotherapy (a type of treatment that uses the immune system to fight cancer) can be helpful in future leukemia patients receiving radiation.PRIMARY OBJECTIVES: I. To identify changes in anti-leukemia immune responses after local radiotherapy to extramedullary sites. II. Develop an annotated biospecimen panel of extramedullary leukemia biopsies prior to and after radiotherapy to examine local immune responses using transcriptional profiling, immunofluorescence and single cell analyses. III. Define changes in the T cell receptor (TCR) clonotypes, functionality and inflammatory cytokine levels in peripheral blood leukocytes and serum. IV. Correlate changes in anti-tumor immune responses with clinic-pathological variables and patient outcomes. SECONDARY OBJECTIVES: I. To ass
Trial Eligibility
Inclusion Criteria: * Patients diagnosed with new or recurrent myeloid leukemia * Aged \>= 18 years old * Eastern Cooperative Oncology Group (ECOG) performance status \< 4 * Patient have measurable and amenable to biopsy under local anesthesia without the need for imaging directed procedure * Ability to understand and provide signed informed consent * Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment. Women of childbearing potential must agree to use an adequate method of contraception during the study and until the last radiation treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and until the last radiation treatment Exclusion Criteria: * Patients who are unwilling to participate * Patients unwilling to undergo the biopsy before or after radiotherapy
Study Info
Organization
M.D. Anderson Cancer Center
Primary Outcome
Changes in anti-leukemia immune responses
Interventions
Locations Recruiting
M D Anderson Cancer Center
United States, Texas, Houston
Interested in joining this trial?
Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.
Get the latest thought leadership on your Acute Myeloid Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.